Bausch & Lomb Incorporated
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bausch & Lomb Incorporated sits in the top decile of US sponsors by registered trial count (#170 of 15,742 sponsors by registered trial count).
Bausch & Lomb Incorporated: 174 sponsored US clinical trials, 3 recruiting.
Bausch & Lomb Incorporated sponsors 174 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 158 completed. 60 of these trials are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myopia, with 9 trials.
Top-decile sponsor footprint
Bausch & Lomb Incorporated ranks in the top decile of sponsors by registered trial count (#170 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
158 of 166 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
174 total, page 1 of 4
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
NCT07168902
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
NCT07128628
IC-8 Apthera IOL New Enrollment Post Approval Study
NCT06060041
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
NCT06978244
Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
NCT06333015
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
NCT06565650
Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
NCT05264623
Revive Toric RWE Study
NCT06785194
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
NCT07054606
A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness
NCT06803654
A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract Extraction
NCT06594185
A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction
NCT06333028
A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy
NCT06346340
A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease
NCT06309953
1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses
NCT06053736
Kalifilcon A Toric Compared to Commercially Available Lenses
NCT06098937
Effects of NOV03 on the Tear Film
NCT05723770
Orientation Characteristics of Daily Disposable Toric Contact Lenses
NCT06069609
Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokeratology Lens
NCT05984290
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
NCT05815758
A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Solution
NCT05565937
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
NCT05591755
Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact Lens
NCT05660577
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
NCT05579730
"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
NCT05360784
1-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compared to Ultra for Presbyopia
NCT05325931
1-Week Dispensing Evaluation of Kalifilcon A Toric Contact Lenses Compared to Ultra for Astigmatism
NCT05320042
Insertion Clinical Study to Evaluate the Orientation Characteristics of Multiple Kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
NCT05129124
2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses
NCT05126953
Biotrue ONEday Contact Lenses With EPG03 Packaging Solution Compared to Biotrue ONEday Contact Lenses
NCT05129488
Insertion Clinical Study to Evaluate the Aberration Characteristics of Kalifilcon A Toric Lenses
NCT05129072
Surface Refractive Index Shift and Lens Absorption/Adsorption of Tear Components of Kalifilcon A Lenses vs Dailies Total1 and Precision1
NCT04840563
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
NCT04567329
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
NCT04140227
Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to Dailies Total 1, Precision 1 and Biotrue ONEday Lenses
NCT04555031
Evaluation of Visual Acuity of the Envista One-piece Acrylic Toric IOL MX60ET
NCT05739656
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
NCT04139798
A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50
NCT04192630
Safety and IOP-Lowering Effects of WB007
NCT04149899
A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop
NCT04175340
Product Performance of a New Silicone Hydrogel Contact Lens
NCT04901897
A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic Astigmatism
NCT04111757
A Study to Evaluate the Safety and Efficacy of Kalifilcon A Daily Disposable Contact Lens
NCT04158466
A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by Participants With Soft Contact Lenses
NCT03897751
A Study to Evaluate the Safety and Effectiveness of a Silicone Hydrogel Custom Contact Lens When Compared to Alden Optical HP Sphere Lens
NCT03897712
Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism
NCT03681808
Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens
NCT03603600
Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)
NCT03511638
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
NCT03489941
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
NCT03896633
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 26 |
| Phase 3 | 46 |
| Phase 4 | 14 |
Therapeutic Areas
What is open in the Bausch & Lomb Incorporated pipeline
3 recruiting of 174 indexed (2% open); 158 completed (91%).
Phase mix: 60 late (III/IV) vs 42 early (I/II) (balanced across stages).
Top condition: Myopia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bausch & Lomb Incorporated: open-pipeline peers nationwide
Peers matched on 174 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Bausch & Lomb Incorporated sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 174 trials (± recruiting share)
- Albert Einstein College of Medicine · 175 trials · 11% recruiting
- UConn Health · 178 trials · 11% recruiting
- Tufts Medical Center · 169 trials · 11% recruiting
- Baylor Research Institute · 180 trials · 17% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
- Eisai · 2% recruiting · 287 trials
- Lexicon Pharmaceuticals · 2% recruiting · 56 trials
- Alcon Research · 2% recruiting · 275 trials
Related
What to do with this Bausch & Lomb Incorporated page
174 registered trials is a research-attention snapshot, not an endorsement of Bausch & Lomb Incorporated or any single study.
- 3 of Bausch & Lomb Incorporated's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Myopia is the condition Bausch & Lomb Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myopia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bausch & Lomb Incorporated pipeline card: 174 registered trials from official public datasets.Report a data error.